VTVT News & Events

The company's cash position as of December 31, 2025, was $88.9M compared to $36.7M as of December 31, 2024. "In 2025, vTv delivered meaningful clinical and corporate progress that positions us for a highly productive 2026," said Paul Sekhri, chairman, president and CEO of vTv Therapeutics. "During the course of the year, we initiated patient dosing in the Phase 3 CATT1 trial evaluating cadisegliatin as an adjunct to insulin for the treatment of type 1 diabetes, strengthened our balance sheet with an $80.0 million financing with leading healthcare investors, and continued to expand our intellectual property estate supporting cadisegliatin. In early 2026, we secured an additional $20.0 million in non-dilutive funding."

vTv Therapeutics announced that it has expanded its license agreement with Newsoara Biopharma to provide Newsoara with global rights to the Company's PDE4 inhibitor, HPP737. Pursuant to the amended license agreement, Newsoara has obtained an exclusive, worldwide license to develop and commercialize Company's PDE4 inhibitor, HPP737, in exchange for an upfront payment and potential future milestone payments and royalties on net sales. In addition to the upfront payment of $20 million, the amended license with Newsoara includes future development milestones of up to approximately $50 million, future sales milestones of up to $65 million, and tiered royalties based on sales.